NEW YORK (GenomeWeb News) — Thallion Pharmaceuticals said today it has sold 80 percent of its stake in its Caprion Proteomics business to a company owned by Great Point Partners, while Thallion will retain the remaining 20 percent of the company.
 
The deal will leave the new company, which will be called Caprion Proteomics, owning “substantially all" of Thallion’s proteomics assets, including the CellCarta platform. It will adopt $22.2 million in Thallion’s long-term debt obligations.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.